Pfizer Inc (PFE)

$26.86 -0.44 (-1.61%)
Market Cap 155.24B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.41
Forward PE 9.14
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 38,542,800
Avg Vol 46,322,383
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 47%
Beta 0.47
Analysts Sell
Price Target $28.82

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
NomadicOptionSeller
NomadicOptionSeller Mar. 13 at 12:11 PM
$PFE $C $PFE is giving me major $C vibes from 2023. When $C was in the $40S: Analysts hated it. Sentiment was awful. Dividend was massive. Then it broke the wedge and started its move. And right now… $PFE looks very similar and has similar hatred
0 · Reply
NomadicOptionSeller
NomadicOptionSeller Mar. 13 at 12:00 PM
$BABA $NVO $BIDU $PFE Here’s 5 value stocks that pay attractive options premium and at safe price levels to WHEEL
1 · Reply
JBS_84
JBS_84 Mar. 13 at 7:03 AM
$PFE 27 tomorrow
0 · Reply
Chemaster
Chemaster Mar. 13 at 4:01 AM
$MAIA The 2028 patent cliff poses a $170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda ($30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g., $173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology ($MAIA) THIO to fill gaps in immuno-oncology pipelines. THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck ($MRK), Bristol Myers Squibb ($BMY), or Pfizer ($PFE) seeking post-cliff growth in a $668B oncology market by 2034. More Information at MAIA Unofficial Reddit Community https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/
0 · Reply
Willieberich
Willieberich Mar. 13 at 2:29 AM
$PFE I would love to see this come back to 26 .to load big time .this looks great .trend is up .if it came back to 26 .it's still in the uptrend ...good luck people .
0 · Reply
NomadicOptionSeller
NomadicOptionSeller Mar. 13 at 1:08 AM
$PFE Redesigning some rooms in the house. I rent practically all my assets. Rent your property. Rent your stock Rent to your business PFE options (rent) will pay for my studio-room this year.
0 · Reply
dom04
dom04 Mar. 13 at 12:22 AM
$PFE back in for 28$ ride.
0 · Reply
parcha
parcha Mar. 13 at 12:12 AM
This dividend-paying pharma stock looks poised for a comeback, charts show $PFE https://www.cnbc.com/2026/03/12/dividend-paying-pharma-stock-looks-poised-for-a-comeback-charts-show.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Mar. 12 at 11:29 PM
$PFE probably down agin at open.
1 · Reply
DragonAlgo
DragonAlgo Mar. 12 at 11:29 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-03-13 | Strike: $26.00 | Type: CALL Option Plan (premium): Entry: $0.86 Stop: $0.62 TP1: $1.12 TP2: $1.47 TP3: $2.08 🔗 https://dragonalgo.com
0 · Reply
Latest News on PFE
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 4 days ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 4 days ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

Mar 7, 2026, 8:15 AM EST - 5 days ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

ADP ARCC BX CAG GLPI MPLX MSFT

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

Mar 6, 2026, 6:05 AM EST - 7 days ago

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

AMD GOOG GOOGL LLY NVDA NVO

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 7 days ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 7 days ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Seven S&P500 Ideal 'Safer' March Dividend Dogs

Mar 4, 2026, 11:31 AM EST - 8 days ago

Seven S&P500 Ideal 'Safer' March Dividend Dogs

AMCR ARE BBY BEN BXP CAG CCI

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

Mar 4, 2026, 9:09 AM EST - 8 days ago

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 8 days ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Pfizer's Quiet Cash Comeback

Mar 3, 2026, 9:50 AM EST - 9 days ago

Pfizer's Quiet Cash Comeback

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 9 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 1:27 PM EST - 10 days ago

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 10 days ago

Pfizer CEO flags issues with FDA's vaccine leadership

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

Mar 2, 2026, 4:51 AM EST - 11 days ago

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

ABBV AMGN AVGO BTI DIV ENB GTY

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

Mar 1, 2026, 8:10 AM EST - 11 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

ARCC BBVA E EQNR ETD FINV GSL

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 13 days ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

Feb 26, 2026, 7:48 AM EST - 14 days ago

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

BBY CAG EQR FRT KEY KMI LYB

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 16 days ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 16 days ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 17 days ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 17 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 17 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 20, 2026, 11:47 PM EST - 20 days ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 22 days ago

Is There 25% Downside For Pfizer Stock?

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Feb 18, 2026, 11:30 AM EST - 22 days ago

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Pfizer: The Rebound Looks Unsustainable

Feb 17, 2026, 5:42 PM EST - 23 days ago

Pfizer: The Rebound Looks Unsustainable

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 24 days ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 4 weeks ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 4 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Pfizer: A Great Opportunity Post Earnings

Feb 11, 2026, 6:08 PM EST - 4 weeks ago

Pfizer: A Great Opportunity Post Earnings

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 4 weeks ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP AMGN BMY ESS HASI HD

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 4 weeks ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 4 weeks ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb 8, 2026, 10:19 PM EST - 4 weeks ago

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 4 weeks ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

Feb 6, 2026, 7:25 AM EST - 4 weeks ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

ARCC ARLP CNQ EPD EQNR F FINV

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 5 weeks ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 5, 2026, 7:09 PM EST - 5 weeks ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 3:00 PM EST - 5 weeks ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 2:02 PM EST - 5 weeks ago

Pfizer: Messy Q4 Earnings Mask An Improving Business

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 5 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 5 weeks ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Feb 3, 2026, 11:56 AM EST - 5 weeks ago

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 5 weeks ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 5 weeks ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 5 weeks ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 5 weeks ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 5 weeks ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 5 weeks ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:18 AM EST - 5 weeks ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

NomadicOptionSeller
NomadicOptionSeller Mar. 13 at 12:11 PM
$PFE $C $PFE is giving me major $C vibes from 2023. When $C was in the $40S: Analysts hated it. Sentiment was awful. Dividend was massive. Then it broke the wedge and started its move. And right now… $PFE looks very similar and has similar hatred
0 · Reply
NomadicOptionSeller
NomadicOptionSeller Mar. 13 at 12:00 PM
$BABA $NVO $BIDU $PFE Here’s 5 value stocks that pay attractive options premium and at safe price levels to WHEEL
1 · Reply
JBS_84
JBS_84 Mar. 13 at 7:03 AM
$PFE 27 tomorrow
0 · Reply
Chemaster
Chemaster Mar. 13 at 4:01 AM
$MAIA The 2028 patent cliff poses a $170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda ($30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g., $173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology ($MAIA) THIO to fill gaps in immuno-oncology pipelines. THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck ($MRK), Bristol Myers Squibb ($BMY), or Pfizer ($PFE) seeking post-cliff growth in a $668B oncology market by 2034. More Information at MAIA Unofficial Reddit Community https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/
0 · Reply
Willieberich
Willieberich Mar. 13 at 2:29 AM
$PFE I would love to see this come back to 26 .to load big time .this looks great .trend is up .if it came back to 26 .it's still in the uptrend ...good luck people .
0 · Reply
NomadicOptionSeller
NomadicOptionSeller Mar. 13 at 1:08 AM
$PFE Redesigning some rooms in the house. I rent practically all my assets. Rent your property. Rent your stock Rent to your business PFE options (rent) will pay for my studio-room this year.
0 · Reply
dom04
dom04 Mar. 13 at 12:22 AM
$PFE back in for 28$ ride.
0 · Reply
parcha
parcha Mar. 13 at 12:12 AM
This dividend-paying pharma stock looks poised for a comeback, charts show $PFE https://www.cnbc.com/2026/03/12/dividend-paying-pharma-stock-looks-poised-for-a-comeback-charts-show.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Mar. 12 at 11:29 PM
$PFE probably down agin at open.
1 · Reply
DragonAlgo
DragonAlgo Mar. 12 at 11:29 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-03-13 | Strike: $26.00 | Type: CALL Option Plan (premium): Entry: $0.86 Stop: $0.62 TP1: $1.12 TP2: $1.47 TP3: $2.08 🔗 https://dragonalgo.com
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Mar. 12 at 11:24 PM
$PFE https://www.fiercebiotech.com/biotech/pfizer-ignite-designed-accelerate-promising-biotech-therapies-fizzles-out
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 12 at 10:38 PM
$PFE - Al’s photo is way better this year! From Uncanny Valley to an actual dude. Well done, Al.
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 12 at 10:36 PM
$PFE - Yay Cool
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:12 PM
$PFE take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
RocroBio
RocroBio Mar. 12 at 7:48 PM
$PFE Looks bearish short term but long term trend is in tact still.
0 · Reply
doubleuptwice
doubleuptwice Mar. 12 at 7:24 PM
$PFE I’m 100% sure what I predicted this week was just a bit off on the timing but will come to fruition. It will be fast , swift, and unchasable.
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Mar. 12 at 6:59 PM
$PFE - NoOoOo OuR bOaT pLs HeLp 😭 Do sOmEtHiNg aLbErT
1 · Reply
Micheal_Pothead
Micheal_Pothead Mar. 12 at 6:14 PM
$PFE Albert new supreme leader confirmed
1 · Reply
NomadicOptionSeller
NomadicOptionSeller Mar. 12 at 6:03 PM
$PFE Is a nice WHEEL position for me. Its chart is primed. I’d likely make more money just holding the stock from here but I can’t turn down the income. 1) All Major daily MAs in-line and UP-sloping 2) Made a higher high 3) Weekly 50 SMA is finally up-sloping Recipe for an uptrend to start.
2 · Reply
doubleuptwice
doubleuptwice Mar. 12 at 5:52 PM
$PFE the wipe out and recovery is hilarious 😂
0 · Reply
Hankjessie
Hankjessie Mar. 12 at 5:32 PM
$PFE I dumped this trash years ago……will buy it back big the second the CEO quits or gets fired…….worst CEO on the planet. Shocked he is still there.
0 · Reply
Micheal_Pothead
Micheal_Pothead Mar. 12 at 4:13 PM
$PFE this is comical
1 · Reply